Radio frequency ablation combined with chemotherapy in the treatment of clinical research of lung tumors / 中国医学装备

Objective:To research on the radio frequency ablation (RFA) combined with the clinical effect of chemotherapy in patients with advanced non small cell lung cancer and lung metastasis. Methods:From 2011 May to 2012 in our hospital 06 months 60 cases of metastatic non-small cell lung cancer and lung cancer patients, divided into radio frequency ablation(RFA) combined with chemotherapy group of 30 cases and a simple chemotherapy group 30 cases, referred to as the treatment group and the control group. To observe the change of tumor volume in patients with poor survival rate, years, tumor recurrence rate, and postoperative complications. Results:Three months after treatment in treatment group tumor recession(CR) in 5 cases(16.7%), part of the recession(PRa) 18(60%), partial mild recession(PRb) 6(20%), no degradation(NR), 1(3.3%), tumor size change significantly better than the control group. The treatment group patients 12 months survival rate was 86.7%, higher than that of the control group(70%). The treatment group of 12 months of tumor recurrence rate of 6.7%, lower than that of the control group(26.7%). No obvious adverse complications of the treatment group of 30 patients after operation. Conclusion:Radiofrequency hyperthermia ablation combined with chemotherapy in treatment of advanced non small cell lung cancer and metastatic lung cancer clinical effect is obvious.

Factors influencing the treatment effect of cancer pain in patients with moderate and severe chronic pain / 中国肿瘤临床

Objective:This study aimed to analyze the factors affecting the outcome of cancer pain in patients with moderate and severe chronic cancer pain for clinical decision making. Methods: Data were collected from 426 cancer patients with moderate and severe chronic cancer pain, and the factors affecting pain treatment were analyzed. Results:A total of 85.6%of patients had good pain control in 3 days (NRS≤3). Multivariate logistic regression models showed that the pain of patients with bone metastases (P=0.026), breakthrough pain after stable pain control (P0.05). Opioid combination with NSAIDs contributed to easier pain control (P=0.024). Digestive system tumors, pain intensity, limb pain, neuropathic pain, use of transdermal fentanyl matrix patch, multiple metastases in stage-IV patients were suggested to be risk factors of pain control in univariate logistic regression models (P<0.05). Conclusion: Bone metastases, breakthrough pain after pain relief, and high dose of MEDD were independent risk factors. Opioid combination with NSAIDs was a protective factor of pain control.